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Sickle cell disease (SCD) is a group of genetic conditions
related to the presence of a sickle hemoglobin (Hb S) muta-
tion (HBB:c.20A>T). People with SCD can be homozygous for
Hb S or can have compound heterozygosity for Hb S with
other gene mutations.1,2 Some hematologic features of SCD
are listed in Table 1, but rare genotypes can also be found.
Since the concentration of Hb S is a pathophysiological factor
of disease severity, the presence of lower concentrations of
Hb S due to double heterozygosity can determine phenotypic
heterogeneity.1,3 However, other genetic and environmental
factors can also have an effect on the disease phenotype.4
Studies looking for abnormal hemoglobins (Hbs) in the
Brazilian population have been performed since the 1950s.5–8
However, the Brazilian Government Directive MS # 822/01
that regulates newborn screening for hemoglobinopathies,
has promoted an increase of data about hemoglobinopathies
in different Brazilian regions.9–11 This associated with the use
of isoelectric focusing electrophoresis (IEF) and high-pressure
liquid chromatography (HPLC) as diagnostic methods, has
enabled the identiﬁcation of an increasing number of abnor-
mal  Hbs as well as compound heterozygous states of Hb S.12–14
An example is a paper published in this issue of the Revista
Brasileira de Hematologia e Hemoterapia that shows data on
a cohort of children with hemoglobin SD pattern.15
Hb D is an abnormal Hb, which migrates to the same
position as Hb S in electrophoresis at alkaline pH, and can
be separated from Hb S in acid pH.16–18 Several Hb D have
been described in different racial groups, but the majority
presented a point mutation in codon 121 of the -globin
gene, which results in the substitution of glutamic acid for
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Hb D-Punjab or Hb D-Los Angeles, however it can also be
named Hb D-North Carolina, Hb D-Chicago, Hb D-Portugal, Hb
D-Cyprus, and Hb D-Oak Ridge.19–21 The estimated prevalence
of Hb D-Punjab is 0.1 to 0.4% in African-Americans.22 In Brazil,
a study of African descendants showed a similar prevalence.5
Sometime after the discovery of Hb D-Punjab, the coinher-
itance of Hb D-Punjab and Hb S was identiﬁed in Caucasian
patients with clinical and hematological manifestations simi-
lar to those of sickle cell anemia (SCA), because this mutation
facilitates Hb S polymerization.23–25 Further clinical studies
conﬁrmed the severity of the manifestations of this associ-
ation and the need to treat these individuals as SCA patients
by prescribing hydroxyurea when indicated.21,26–29
There are other types of Hb D due to different point muta-
tions in the -globin gene, such as Hb D-Iran (HBB:c.67G>C)
and Hb D-Ibadan (HBB:c.263C>A). However, individuals with
these mutations have normal hematologic values and do not
suffer from vaso-occlusive complications, since their red cells
do not sickle under physiologic conditions.18,30,31
Hb Korle-Bu (Hb KB) or Hb G-Accra (HBB:c.220G>A) is a fre-
quent mutation in Sub-Saharan Africa.32,33 This Hb has the
same IEF mobility as Hb D-Punjab but can be differentiated
by HPLC. Heterozygotes for Hb KB have no hematologic alter-
ations, and individuals with double heterozygosis Hb S-Hb KB
have normal red cells on blood smear and a benign clinicalimental, Disciplina de Hematologia e Hemoterapia, Universidade
la Clementino, 04037-002 São Paulo, SP, Brazil.
in the gelation of Hb S.33,34
Interestingly, the Hb KB mutation [beta73(E17)Asp→Asn]
can occur in addition to the Hb S mutation [beta6(A3)Glu6Val]
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
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Table 1 – Hematological features of some sickle hemoglobinopathies.
Genotype PCV (%) Retic (%) MCV (fL) Hb F (%) Hb A2 (%) % Variant Severitya
SCA 25 8 90 5 3 >90% Hb S ++++
Hb SC disease 35 3 80 2 3 50% Hb S, 50% Hb C ++
S-0 thalassemia 27 7 82 7 5 90% Hb S ++++
S-+ thalassemia 38 2 70 2 6 5–30% Hb A ++
SCA- thalassemia 30 6 78 5 5 >90% Hb S +++
Hb SE disease 35 3 75 2 3 ∼30% Hb E ++
Hb SD disease* 20 86 1–10 2–4 45% Hb S, 45% Hb D +++
Sickle cell trait 45 1 85 1 2 60% Hb A, 40% Hb S
SCA: sickle cell anemia; PCV: packed cell volume; Retic: reticulocyte count; MCV: mean cell volume; Hb: Hemoglobin.
a Severity of disease rated from most severe (++++) to absence of clinical events ( ) includes complications related to sickle vaso-occlusion and
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Table modiﬁed from 1 with * data obtained from 21,27,32.
n the same beta globin chain. In this case, this Hb with a dou-
le mutation is termed Hb C-Harlem (or Hb C-Georgetown)
HBB:c.20A>T, HBB:c.220G>A), because it migrates to the posi-
ion of Hb C in cellulose acetate electrophoresis at alkaline pH.
ndividuals heterozygous for Hb C-Harlem are asymptomatic,
ut the coinheritance of Hb S and Hb C-Harlem has clinical
anifestations similar to SCA.20,32,35
Researchers from India and the Middle East are the main
uthors of the few papers about Hb SD-Punjab; there are less
ata published about the association Hb S-Hb KB.21,27–29,34,36–41
y studying two different groups of patients with Hb SD pat-
erns, speciﬁcally Hb SD-Punjab and Hb S-Hb KB, Rezende et al.
ot only published important clinical data about the coinher-
tance of two rare Hb but also pointed out the importance of
his differential diagnosis.15
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